December 12, 2016
Bayer and Versant Ventures to launch BlueRock Therapeutics
Bayer AG and Versant Ventures have announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
December 12, 2016
Novartis’s Monaleesa study show PFS in breast cancer treatment
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…
December 12, 2016
Achaogen passes US and European hurdles to market its plazomicin antibiotic
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
December 12, 2016
Alvogen’s flu capsules alternative for Tamiflu
Alvogen on Monday launched the first flu capsules, generic equivalent to Roche’s Tamiflu (oseltamivir phosphate) capsules in the United States.
December 12, 2016
Ipsen science boss, R&D Vice President Claude Bertrand leaves
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
December 12, 2016
Eli Lilly and AstraZeneca join forces to fight Alzheimer’s disease
Eli Lilly and AstraZeneca have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which…
December 12, 2016
Short: Sycomore Asset Management’s share of Biocartis trigers transparency act
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…
December 12, 2016
Mereo balance sheet strong, sufficient funds for clinical tests
Mereo BioPharma Group, a clinical stage, UK-based biopharmaceutical company focused on rare diseases, is looking to strengthen its rare and specialty disease…
December 12, 2016
Herantis gets funds for its Parkinson’s disease study
The research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for…
December 12, 2016
Novartis combination against age-related vision loss fails tests
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…